On November 4, Clorox rose 5.32% in Regular Trading, trading at $98.88/share, with turnover of $82.87 million.

The clearest catalyst was a strong fiscal first-quarter report followed by fresh analyst target-price increases. Clorox reported adjusted EPS of $1.55 on revenue of $1.91 billion, ahead of consensus estimates of $1.07 and $1.88 billion, respectively. The company reiterated fiscal 2027 guidance, while indicating adjusted EPS is likely to land near the low end of the $5.70 to $6.00 range as cost pressures persist.

Subsequent analyst reactions were constructive but measured: Deutsche Bank raised its price target to $99 from $95 and maintained Hold, while BNP Paribas lifted its target to $98 from $89. Earlier, Evercore ISI upgraded the stock to In Line with a $99 target. Even so, several research notes emphasized ongoing uncertainty around organic sales durability, inflation, and margin pressure into fiscal Q2 and fiscal 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)